The Life Sciences Report

Other Streetwise Reports

The Gold Report The Energy Report The Life Sciences Report The Mining Report

Today's Featured Company

Can-Fite BioPharma Ltd.: (CANF:NYSE.MKT) Can-Fite BioPharma Ltd. is an advanced clinical stage drug development company with a platform technology that addresses multibillion dollar markets in the treatment of cancer, inflammatory and other diseases. The company is in Phase 2/3 trials for psoriasis and Phase 2 trials for liver cancer. Study design for a Phase 3 trial in rheumatoid arthritis has been completed. Can-Fite has been granted orphan drug designation by the U.S. FDA for its liver cancer drug, which is approved for compassionate use by Israel's Ministry of Health. The company's drug candidates have an excellent safety profile with experience in over 1,200 patients. More >

Streetwise Expert Interviews

Watchlist Analysts Forecast Continued Blue Sky for Biotech Industry

For the last two years the biotech sector has experienced market-beating gains, even taking into account the industry-wide hiccup in early 2014. Can this trend continue? The five analysts who selected names for The Life Sciences Report's 2015 Small-Cap Biotech Watchlist spend their days considering this question; it comes into play with every recommendation they make. The topic came up in various contexts during the Watchlist panel at the 2015 Biotech Showcase: Here are four factors investors should consider as they move into 2015.

(1/29/15) More >

The Small-Cap Biotech Watchlist 2015 Unwrapped: Who Are These Guys? And Why Are They Here?

At the Biotech Showcase 2015 in San Francisco, five biotech analysts examined the burgeoning small-cap life sciences marketplace and found every reason to believe its good health would continue into 2015 and beyond. The experts also sent investors who attended the panel discussion of The Life Sciences Report's 2015 Small-Cap Biotech Watchlist home with a bundle of robust investment opportunities, including a few new names. Read on to see which companies made the list, and why.

(1/27/15) More >

Convert Catalysts into Profits: Sagient Research's Edward Stopke

The biotech sector is teeming with companies racing to bring the hot new drug or therapy to the marketplace, and Edward Stopke has a list of companies with catalytic moments in the making. (1/22/15) More >

Newsletter Briefs

"CANF's oral psoriasis candidate has shown some very, very promising data." (1/27/15) Can-Fite BioPharma Ltd. - The Life Sciences Report Interview with Reni Benjamin More >

"There is opportunity for the FDA to accept a new drug application filing from SNSS." (1/27/15) Sunesis Pharmaceuticals Inc. - The Life Sciences Report Interview with Mara Goldstein More >

"THLD's Phase 3 soft tissue sarcoma trial is likely to play out with topline results by Q3/15 or Q4/15." (1/27/15) Threshold Pharmaceuticals Inc. - The Life Sciences Report Interview with George Zavoico More >

"ATHX completed enrollment in its Phase 2 stroke study before the new year, so the first 90-day results will emerge in Q1/15E." (1/22/15) Athersys Inc. - The Life Sciences Report Interview with Edward Stopke More >

"The research synergy with Gilead and Merck could prove fruitful for RNN in terms of acquisition potential." (1/22/15) Rexahn Pharmaceuticals Inc. - The Life Sciences Report Interview with Edward Stopke More >

"If all goes well, CUR's NSI-189 product will move into Phase 2 development in Q2/15, so that is a good advancement opportunity." (1/22/15) Neuralstem Inc. - The Life Sciences Report Interview with Edward Stopke More >

"RNN's RX-3117 showed the ability to stop tumor growth from 62–100%." (1/13/15) Rexahn Pharmaceuticals Inc. - Sharon di Stefano, Seeking Alpha More >

"The vote of confidence CTH has received from The Michael J. Fox Foundation is very advantageous." (1/8/15) Cynapsus Therapeutics Inc. - The Life Sciences Report Interview with Daniel Pearlstein More >

Expert Analysis

"ATHX's stock should benefit from the £2M grant from Innovate UK." (1/22/15) Athersys Inc. - Henry McCusker, Regenerative Medicine Investors More >

"New results help define the potential for THLD's Phase 3 success." (1/27/15) Threshold Pharmaceuticals Inc. - Jerry Isaacson, LifeSci Advisors More >

"Good data in stroke should be transforming for ATHX." (1/23/15) Athersys Inc. - Jason Kolbert, Maxim Group More >

"2014 was a successful year for INO." (1/17/15) Inovio Pharmaceuticals Inc. - Jason Russ, Seeking Alpha More >

"NHC's Q4/14 revenue of $39.2M was a significant positive surprise." (1/13/15) Nobilis Health Corp. - Keith Hinton, Sidoti & Company More >

"MSB started a Phase 3 trial in chronic lower back pain due to DDD." (1/15/15) Mesoblast Ltd. - Jason Kolbert, Maxim Group More >

"CUR is roughly on schedule with its clinical trials in four diseases." (1/13/15) Neuralstem Inc. - Larry Smith, SmithOnStocks More >

"NHC's estimated Q4/14 sales were up 109% versus those of Q4/13." (1/13/15) Nobilis Health Corp. - Steven Ralston, Zacks Small-Cap Research More >